segunda-feira, 9 de novembro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document

Everyone Just Missed a Major Announcement From Meta Platforms

View original at fool.com
Motley Fool - Stock Analysis Title: Everyone Just Missed a Major Announcement From Meta Platforms Date: 2026-07-31 20:13 Source: https://www.fool.com/investing/2026/07/31/everyone-just-missed-a-major-meta-announcement/?source=iedfolrf0000001 <p><strong>Meta Platforms</strong> <span class="ticker">(NASDAQ: META)</span>…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • This cloud computing launch has long been rumored and could be the thing Meta's stock needs to pull it out of a major sell-off.

    60% confidence

  • The author remains bullish on Meta despite the disappointing quarter, because its AI offerings haven't had a chance to take off yet.

    60% confidence

  • The stock tumbled the day after earnings, mainly due to weak bottom-line earnings and a smaller-than-expected revenue forecast for Q3.

    60% confidence

  • Most investors completely missed a huge announcement from Meta Platforms: an upcoming cloud computing business.

    60% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Q4 2026 Biotech Catalyst Cycle: Data Readouts, FDA Decisions and Capital-Allocation Shifts
From late October to January, mid-cap biotechs move through a dense run of events: ESMO and AHA/AASLD data presentations, Q3 earnings, and FDA PDUFA dates for ivonescimab (Nov 14) and lorundrostat (Dec 22). Alongside the regulatory news, companies are changing how they allocate capital: one lowered FY2026 R&D and SG&A guidance and pushed milestones into 2027, one authorized a $400M buyback, and one scheduled a delisting vote (EGM Nov 19, application Jan 25). Value is concentrating in a few binary regulatory and Phase 3 outcomes (Maritime-1 and ECLIPSE 2/3 readouts around Q1 2027), so sentiment is mixed.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,996
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,996 factos verificados com a fonte5,558 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Everyone Just Missed a Major Announcement From Meta Platforms — Source | Via News | pt.VIA.NEWS